Tuberculosis Preventive Therapy for Individuals Exposed to Drug-resistant Tuberculosis: Feasibility and Safety of a Community-based Delivery of Fluoroquinolone-containing Preventive Regimen
Tuberculosis Preventive Therapy for Individuals Exposed to Drug-resistant Tuberculosis: Feasibility and Safety of a Community-based Delivery of Fluoroquinolone-containing Preventive Regimen
复制标题
DOI：
10.1093/cid/ciz502
复制
发表时间：
2020-05-01
影响因子：
11.8
通讯作者：
Hussain, Hamidah
中科院分区：
文献类型：
--
作者：
Malik, Amyn A.;Fuad, Junaid;Hussain, Hamidah
背景资料：观察性研究已经证明了基于氟喹诺酮类药物的治疗方案对治疗可能感染耐药结核病（DR-TB）的个体的有效性。我们试图评估这种方法在南亚城市环境中的可行性。方法：从2016年2月至2017年3月，在印度河医院登记的耐药结核病患者的所有家庭接触者在家中接受结核病症状筛查。对0-17岁的儿童、有症状的成人和免疫功能低下的患者（人类免疫缺陷病毒、糖尿病或营养不良）进行结核病评估。被诊断患有结核病的接触者开始接受治疗。年龄≥ 18岁且免疫力低下的无结核病接触者接受6个月的氟喹诺酮类药物治疗。结果：纳入100个家庭，800名接触者：353名（44.1%）年龄
Background: Observational studies have demonstrated the effectiveness of a fluoroquinolone-based regimen to treat individuals presumed to be infected with drug-resistant tuberculosis (DR-TB). We sought to assess the feasibility of this approach in an urban setting in South Asia.Methods: From February 2016 until March 2017, all household contacts of DR-TB patients enrolled at the Indus Hospital were screened for TB symptoms at home. Children aged 0-17 years, symptomatic adults, and those with an immunocompromising condition (human immunodeficiency virus, diabetes, or malnutrition) were evaluated for TB disease. Contacts diagnosed with TB disease were started on treatment. Contacts without TB disease aged = 18 years with an immunocompromising condition were offered 6 months of treatment with a fluoroquinolone.Results: One hundred households with 800 contacts were enrolled: 353 (44.1%) individuals aged